Nghiên cứu giai đoạn III đa trung tâm, ngẫu nhiên, có kiểm soát về sự kết hợp giữa chặn androgen với và không có axit zoledronic ở bệnh nhân ung thư tiền liệt tuyến có bệnh di căn đến xương: kết quả của thử nghiệm ZAPCA

Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3–13 Gnant M (2012) Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep 14:35–43 Michaelson MD, Kaufman DS, Lee H et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038–1042 Saad F, Gleason DM, Murray R et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468 Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882 Gnant M, Mlineritsch B, Schippinger W et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691 Coleman R, de Boer R, Eidtmann H et al. (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398–405 Coleman R, Cameron D, Dodwell D et al. (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15:997–1006 Wirth M, Tammela T, Cicalese V et al. (2015) Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 67:482–491 Dearnaley DP, Mason MD, Parmar MK et al. (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872–876 Smith MR, Halabi S, Ryan CJ et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143–1150 James ND, Sydes MR, Clarke NW et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177 Soloway MS, Hardeman SW, Hickey D et al. (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195–202 Eisenberger MA, Blumenstein BA, Crawford ED et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042 Kotake T, Usami M, Akaza H et al. (1999) Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Jpn J Clin Oncol 29:562–570 Usami M, Akaza H, Arai Y et al. (2007) Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 10:194–201 Schoenfeld DA (1983) Sample-size formula for the proportional-hazards regression model. Biometrics 39:499–503 Dearnaley DP, Sydes MR, Mason MD et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95:1300–1311 Vale CL, Burdett S, Rydzewska LH et al. (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243–256 Thompson IM, Tangen C, Basler J et al. (2002) Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168:1008–1012 Morgan GJ, Davies FE, Gregory WM et al. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989–1999 Noguchi M, Kikuchi H, Ishibashi M et al. (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195–201 Smith MR, Saad F, Coleman R et al. (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39–46 Vahtsevanos K, Kyrgidis A, Verrou E et al. (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362